Obesity

Biomarker Basics

As this blog focuses on reviewing scientific papers describing biomarker discovery, validation and clinical use, we felt that it was time to pause and review some biomarker basics.

What is a biomarker? A biomarker can be objectively measured to assess a biologic process, a disease process, or a response to a treatment or lifestyle change.1 Almost […]

Amlexanox, Obesity and the IKK-e and TBK1 Signalling Pathway

Previous posts have described some of the novel strategies and innovative technologies used to identify candidate biomarkers and therapeutic targets. But what comes next? How can researchers verify that putative biomarkers are biologically relevant and worthy of further research? Shannon Reilly et al.,1 deconstruct the signalling pathway that mediates obesity-induced inflammation, and elegantly demonstrate that […]

By |October 20th, 2015|Obesity|0 Comments

Anti-inflammatory Drugs Might Someday Treat Obesity

Obesity leads to chronic, low-grade local inflammation in the liver and adipose tissue. This local inflammation eventually results in insulin resistance and the development of type 2 diabetes. American researcher Jonathan Mowers and his team1 explored the complex molecular pathways linking obesity, inflammation and diabetes. Their investigation identified two potential therapeutic targets.

Previously, these researchers observed […]

By |October 7th, 2015|Diabetes, Obesity|0 Comments

Measuring IGF1 – Future Direction for MS in the Clinical Lab

The peptide hormone insulin-like growth factor 1 (IGF1) is involved in a wide spectrum of biological processes.1 It is present in nanomolar amounts in blood. IGF-binding proteins modulate IGF1. Because the hormone is a marker for multiple disorders including osteoporosis, diabetes, obesity, neuromuscular disorders, growth hormone resistance and insulin resistance, accurate measurement of IGF1 levels […]

By |September 21st, 2015|Diabetes, Obesity|0 Comments